Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of BAY 1817080 in Renal Impairment
NCT04471337Phase 1Completed
- Sponsor
- Bayer
- Start
- Aug 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of eliapixant in refractory chronic cough (RCC), overactive bladder (OAB), endometriosis and 1 more (4 arms), sponsored by Bayer. Primary endpoints: Area Under the Curve, unbound at Day 1 and Maximum Concentration, unbound at Day 1. Started Aug 2020; status: completed.
02
Drugs
eliapixant
03
Conditions
refractory chronic cough (RCC)overactive bladder (OAB)endometriosisdiabetic neuropathy
Beyond the preview
Go deeper on NCT04471337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04471337.